CEBPA Mutation Analysis
Also known as: CEBPA
Use
CCAAT/enhancer‑binding protein alpha (CEBPA) mutations are detected in about 7‑15% of patients with acute myeloid leukemia (AML). Double (biallelic) mutations are associated with good prognosis in patients with intermediate‑risk and normal cytogenetics who do not have FLT3‑ITD mutations. This test aids in assessing the prognosis of newly diagnosed AML patients with normal or intermediate‑risk cytogenetics.
Special Instructions
Includes SNP genotype reporting at rs34529039, with plasma testing for enhanced sensitivity. Test is DNA‑based. Please select Extract & Hold ‑ DNA if specimen hold service is desired. For FFPE: paraffin block is preferred; do not use zinc fixatives. If submitting slides, use positively‑charged slides and 10% NBF fixative. Block and slide identifiers should match specimen ID on requisition. Use cold pack for transport; refrigerate fresh samples before shipping, ship same day; do not freeze.
Limitations
Not provided.
Methodology
PCR-based (PCR)
Biomarkers
Result Turnaround Time
10 days
Related Documents
For more information, please review the documents below
Specimen
Bone Marrow
Volume
2 mL
Minimum Volume
Not provided
Container
EDTA tube
Storage Instructions
Refrigerate before shipping; ship same day; use cold pack not contacting specimen; do not freeze